ESC 365 - Introduction, recap and overview of evidence for SGLT2 inhibitors in HFrEF.

Open Access

Introduction, recap and overview of evidence for SGLT2 inhibitors in HFrEF.

Session: SGLT2 inhibitors in practice (part 3): the case for early intervention in HFrEF

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Professor J. Butler (Dallas, US)

Sponsored by Boehringer Ingelheim & Eli Lilly

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

136 presentations

35 followers

2 more presentations in this session

Implementing an SGLT2i for HFrEF treatment in my practice.

Speaker: Professor A. Stewart Coats (Sydney, AU)

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

SGLT2 inhibitors in practice (part 3): the case for early intervention in HFrEF

Speakers: Professor J. Butler, Professor A. Stewart Coats, Professor S. Anker

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

novartis

Explore sponsored resources